Skip to content

Search

2017 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2017 Round 2 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

2017 Round 1 Seed Funding Recipients

Congratulations goes to Dr Asha Bowen and Dr Ruth Thornton for being the successful first round recipients of the WCVID.

2016 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2016 Round 2 Wesfarmers Centre Seed Funding.

2015 Seed Funding Recipients

Eight applicants were successful, and were awarded $15,000 each for activities supporting subsequent research grant applications.

2014 Seed Funding Recipients

In 2014, the Wesfarmers Centre of Vaccines & Infectious Diseases put out a first call for seed funding proposals.

Spritz-OM

Preventing over half of the world’s ear infections with a therapy such as Spritz-OM will significantly improve health and educational outcomes on a global scale.

The STAMP RSV Program

STAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.

RSV Immunisation Guidance Tool

This tool is designed to help current and future parents and caregivers as well as health care providers. It is currently based on the 2025 Western Australian RSV immunisation program.

Variants of Streptococcus pneumoniae Serotype 14 from Papua New Guinea with the Potential to Be Mistyped and Escape Vaccine-Induced Protection

Streptococcus pneumoniae (the pneumococcus) is a human pathogen of global importance, classified into serotypes based on the type of capsular polysaccharide produced. Serotyping of pneumococci is essential for disease surveillance and vaccine impact measurement.

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review

The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.